No abstract

No abstract

No abstract

Introduction: We hypothesized that inositol hexaphosphate (IP6) would modulate cell cycle and cellular growth in bladder cancer. Materials and Methods: Bladder cancer cell lines were treated with 2.5 or 4.5 mM/well IP6. Cell viability was measured by MTT at 24 and 48 h. Cell cycle analysis was measured by DNA staining and quantified by FACS analysis. Results: Cell growth was inhibited in the TCCSUP, HTB9 and T24 cells (p < 0.001) with the exception of the HTB9 cells at 24 h. G1 phase fractions increased in the TCCSUP and HTB9 cells, while S phase fraction was decreased (p < 0.001). G2 phase was decreased in the TCCSUP cells (p < 0.001). G1 phase fraction was decreased in the T24 line with 4.5 mMIP6 (p < 0.001), while a significant increase in the S phase was observed in the T24 cells (p < 0.001). Conclusions: These results indicate that IP6 is potentially a highly effective treatment for carcinoma of the bladder.

Prostate cancer is usually diagnosed when elevated PSA levels lead to a TRUS biopsy. We present a case in which there were several negative biopsies and a rising PSA. This led to a multiparametric MR (mpMRI) which demonstrated a large mass which originated in the anterior transition zone and had extended through the anterior fibromuscular stroma and prostate capsule with a significant extra-prostatic component. The mass was successfully approached anteriorly with a CT-guided biopsy. The patient was subsequently successfully treated with radiotherapy utilizing MR in the planning process. This case report summarizes the utility of mpMRI in this clinical setting. For patients with high suspicion of prostate malignancy despite prior negative biopsies, it can identify tumor in locations not amenable to TRUS biopsy. It also is critical for accurate radiation treatment planning, allowing for increased confidence in tumor targeting as well as sparing sensitive normal tissue.